gms | german medical science

Meeting Abstract (OP140)

A phase III randomized trial of carboplatin/paclitaxel, with or without bexarotene (Targretin), in chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer (NSCLC)

Reck M, Blumenschein Jr. G, Jotte R, von Pawel J, Miller WH, Khuri F, Rigas JR, Negro-Vilar A, Gatzemeier U

[Abstract] [Full Text] [XML]

Meeting Abstract (OP141)

Long Term Results of Lung Cancer Treatment - Clinical and Population-Based Aspects

Schmidt M, Hölzel D

[Abstract] [Full Text] [XML]

Meeting Abstract (OP142)

Hypofractionated stereotactic radiotherapy (hSRT) of NSCLC Stage I

Zimmermann F, Geinitz H, Schill S, Schratzenstaller U, Nieder C, Molls M

[Abstract] [Full Text] [XML]

Meeting Abstract (OP143)

Identification of patients potentially benefiting from concomitant EGF-R inhibition and chemotherapy: CHALLENGE trial: Erlotinib followed by Gemcitabine/Cisplatin +/- Erlotinib induction in patients with NSCLC IIIA (N2)/IIIB (N3) monitored by microarray analyses

Overbeck TR, Danner B, Dörge H, Wenleder S, Hemmerlein B, Meller J, Baum RP, Wolf J, Schirren J, Müller RP, Wolf M, Griesinger F

[Abstract] [Full Text] [XML]

Meeting Abstract (OP144)

Single-Agent (SA) Therapy of Docetaxel (D) and Gemcitabine (G) for Patients (pts) in Advanced Non-small Cell Lung Cancer (NSCLC): Results of Three Consecutive Randomized Multicentre Trials

Manegold C, Thatcher N, Kortsik C, Koschel G, Mezger J, Schott von Römer K, Pilz LR

[Abstract] [Full Text] [XML]

Meeting Abstract (OP145)

Gefitinib for treatment of non small cell lung cancer (NSCLC): Single center clinical results and mutation analysis of the epidermal growth factor receptor (EGFR) kinase domain

Frickhofen N, Neugebauer B, Hengstler S, Labenz S, Fuhr HG, Schirren J, Fisseler-Eckhoff A, Serve H, Müller-Tidow C

[Abstract] [Full Text] [XML]

Meeting Abstract (OP146)

First- and Secondline chemotherapy with Pemetrexed alone or in combination with Carboplatin in malignant pleural mesothelioma

Storbeck B, Gatzemeier U, Reck M

[Abstract] [Full Text] [XML]

Meeting Abstract (PO147)

Epoetin alfa (EPO) and survival in patients with non-resectable NSCLC – Interim results

Debus J, Hindermann S, Morr H, Mezger J, Sebastian M, Angermund R, Drings P

[Abstract] [Full Text] [XML]

Meeting Abstract (PO148)

Intensity-modulated Radiotherapy (IMRT) of Lung Tumors in 50 Patients: Protection of Lung Tissue and low Toxicity

Huhnt W, Buchali A

[Abstract] [Full Text] [XML]

Meeting Abstract (PO149)

Side effects of hypofractionated extracranial stereotactic radiotherapy (ESRT) of malignant tumours of the lung

Zimmermann F, Geinitz H, Schill S, Schratzenstaller U, Thamm R, Molls M

[Abstract] [Full Text] [XML]

Meeting Abstract (PO150)

Sorafenib (BAY 43-9006) in Patients with Relapsed or Refractory Advanced Non-Small-Cell Lung Carcinoma – a phase II study

Reck M, Blumenschein Jr. G, Bernard I, Scheuring U, Gatzemeier U

[Abstract] [Full Text] [XML]

Meeting Abstract (PO151)

Single institution experience in advanced non-small cell lung cancer (NSCLC) patients (pts) with erlotinib (Tarceva®) within a large extended access programme* (EAP)

Gauler TC, Tewes M, Sailer V, Bildat S, Schütt P, Korfee S, Stattaus J, Toetsch M, Seeber S, Eberhardt W

[Abstract] [Full Text] [XML]

Meeting Abstract (PO152)

First experiences with oral tyrosine kinase inhibitor Erlotinib in patients with advanced Non small cell lung cancer within an Expanded Access Program (EAP Germany)

Schneider CP

[Abstract] [Full Text] [XML]

Meeting Abstract (PO153)

Correlation of PTTG-1 expression with survival in small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC)

Geddert H, Rehfeld N, Atamna A, Rohrbeck A, Gabbert HE, Kronenwett R, Haas R, Rohr UP

[Abstract] [Full Text] [XML]

Meeting Abstract (PO154)

Genetic-based classification of lung cancer: correlation between nuclear DNA content, chromosomal alterations and morphology

Amin Kotb WFM, Petersen I

[Abstract] [Full Text] [XML]

Meeting Abstract (PO155)

Single-agent chemotherapy with Mitomycin for advanced non-small cell lung cancer patients with reduced Performance Status

Guschall WR, Dittrich I

[Abstract] [Full Text] [XML]

Meeting Abstract (PO156)

Tumor specific MUC1 glycosylation correlates with improved post-surgical survival of non-small cell lung cancer patients with lymphatic or distant metastasis

Wiewrodt R, Kuemmel A, Single K, Bittinger F, Faldum A, Sebastian M, Taube C, Goletz S, Buhl R

[Abstract] [Full Text] [XML]

Meeting Abstract (PO157)

Retrospective analysis of second-line chemotherapy in relapsed NSCLC patients who had received first-line paclitaxel/carboplatin chemotherapy in a randomized phase III trial

Nagel S, Raziq H, Blankenburg T, Schaedlich S, Schuette W

[Abstract] [Full Text] [XML]

Meeting Abstract (PO158)

Predictive factors for patients with small cell lung carcinoma (SCLC) undergoing first-line ACE chemotherapy – results after long term follow-up of median 7.5 years

Brueckl WM, Herbst L, Lechler A, Zirlik S, Fuchs F, Brunner T, Klein P, Papadopoulos T, Hohenberger W, Hahn EG, Wiest GH

[Abstract] [Full Text] [XML]

Meeting Abstract (PO159)

Clinical experience with Erlotinib

Neuhaus T, Tuohimaa A, Ko Y

[Abstract] [Full Text] [XML]

Meeting Abstract (PO160)

Successful in-patient rehabilitation of lung cancer patients - predictors and outcome

Riesenberg H, Lübbe AS

[Abstract] [Full Text] [XML]

Meeting Abstract (PO161)

Fast response of chemotherapy-refractory bronchiolo-alveolar carcinoma to erlotinib

Gütz S, Schwartz EK, Gutjahr K, Gillissen A

[Abstract] [Full Text] [XML]

Meeting Abstract (PO162)

Pulmonary mucinous cystadenocarcinoma – a rare disease successfully treated by thoracoscopic approach?

Möbius C, Ott R, Winkler J, Tannapfel A, Hauss J, Eichfeld U

[Abstract] [Full Text] [XML]

Meeting Abstract (PO163)

Präoperatives Staging des nicht-kleinzelligen Bronchialkarzinoms mit PET/CT

Buck AK, Blumstein NM, Blümel C, Glatting G, Pauls S, Mottaghy FM, Halter G, Sunder-Plassmann L, Reske SR

[Abstract] [Full Text] [XML]

Meeting Abstract (PO164)

Tumorgrading: An important prognostic factor in diagnostic of non-smal-cell-lung-cancer, stadium pT1

Neugebauer B, Schirren J, Beqiri S, Fisseler-Eckhoff A

[Abstract] [Full Text] [XML]